Compared with intermediate-acting SGLT2 inhibitors, the long-acting inhibitors can reduce daily blood glucose excursion, protect pancreatic function, and improve glucose tolerance and insulin resistance (61). The gene discussed is SLC5A2; the disease is Insulin resistance.